Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.32 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559729 | 1.00 | ERN1 (0.41) | ERN1EGFRALDH1A1KDM4ETSHR | |
| SCHEMBL25398720 | 0.82 | EGFR (0.38) | EGFRALDH1A1TDP1CYP17A1PDPK1 | |
| SCHEMBL29071990 | 0.80 | EGFR (0.37) | EGFRCYP17A1PDPK1 | |
| SCHEMBL32677379 | 0.80 | EGFR (0.37) | EGFRCYP17A1PDPK1 | |
| SCHEMBL1475089 | 0.79 | MAP3K7 (0.36) | ERN1 | |
| SCHEMBL31521747 | 0.74 | CYP17A1 (0.39) | ERN1EGFRALDH1A1TSHRTDP1 | |
| SCHEMBL30753544 | 0.74 | POLB (0.35) | — | |
| SCHEMBL27081736 | 0.74 | POLB (0.35) | — | |
| SCHEMBL20345724 | 0.73 | CYP17A1 (0.37) | ERN1EGFRALDH1A1TDP1CYP17A1 | |
| SCHEMBL6338655 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-05 | — | — | US | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| EP-4313994-B1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-05 | — | — | EP | disclosed |
| US-20240199635-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-20 | — | — | US | disclosed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| CN-117069720-A | 5-HT 2A Receptor agonist, preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116829550-A | Pyrimidine-2-ylsulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
| WO-2021059017-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| EP-1959959-B1 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | disclosed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
| EP-1959959-A2 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067511-A2 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| EP-0408034-B1 | 3-Substituted vinyl cephalosporin derivatives | EISAI CO LTD (JP) | 1996-05-01 | — | — | EP | disclosed |
| US-5151417-A | Antibiotics and bactericides | EISAI CO., LTD. (JP) | 1992-09-29 | — | — | US | disclosed |
| CN-1048706-A | 3-substituted vinyl cephalosporin derivatives and preparation method thereof | EISAI CO LTD (JP) | 1991-01-23 | — | — | CN | disclosed |
| EP-0408034-A1 | 3-Substituted vinyl cephalosporin derivatives | Eisai Co., Ltd. (JP) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | DDR1, DDR2, DDRGK1 | ERN1 1465/4885EGFR 44/4885ALDH1A1 3606/4885 |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | ERN1 2012/4885EGFR 4036/4885ALDH1A1 3523/4885 |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | PROKR2, PROKR1, NTSR2 | ERN1 3878/4885EGFR 4085/4885ALDH1A1 4629/4885 |
| US-20240199635-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | ERN1 1537/4885EGFR 223/4885ALDH1A1 3941/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | ERN1 2012/4885EGFR 4036/4885ALDH1A1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.